SCHEMBL1407384

SCHEMBL1407384

COc1ccc(-c2c3cccc(F)c3nn2Cc2c(F)cccc2Cl)c(OC)c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
LMNA P02545 3/20 0.45
ALDH1A1 P00352 3/20 0.43
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 2/20 0.39
GAA P10253 1/20 0.39
RAB9A P51151 1/20 0.39
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39
BUB1 O43683 1/20 0.39
SLC22A12 Q96S37 1/20 0.38
NR1H2 P55055 1/20 0.38
NR1H3 Q13133 1/20 0.38
RORC P51449 1/20 0.37
NPBWR1 P48145 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1408171 0.90 KMT2A (0.48) KMT2AMEN1LMNAALDH1A1HPGD
SCHEMBL1407762 0.89 NR1H2 (0.48) ALDH1A1HPGDKDM4EGAAMAPT
SCHEMBL1407475 0.87 NR1H2 (0.46) LMNAALDH1A1HPGDTSHRKDM4E
SCHEMBL1407455 0.87 NR1H2 (0.45) KMT2AMEN1ALDH1A1L3MBTL1KDM4E
SCHEMBL1407428 0.86 NR1H2 (0.47) KMT2AMEN1ALDH1A1HTTKDM4E
SCHEMBL1414643 0.85 NR1H2 (0.48) LMNAALDH1A1RAB9AMAPTNR1H2
SCHEMBL1407447 0.85 NR1H2 (0.47) KMT2AMEN1LMNAALDH1A1HPGD
SCHEMBL1408297 0.84 NR1H2 (0.43) KMT2AMEN1LMNATSHRKDM4E
SCHEMBL1407316 0.83 P2RX7 (0.40) KMT2AMEN1ALDH1A1L3MBTL1KDM4E
SCHEMBL1407321 0.83 NR1H2 (0.47) KMT2AMEN1ALDH1A1HTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US claimed
EP-1773781-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES Wyeth (US) 2007-04-18 EP claimed
WO-2006017384-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES WYETH (US) 2006-02-16 WO claimed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US claimed
EP-2295429-A1 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases Wyeth LLC (US) 2011-03-16 EP disclosed
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US disclosed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases NR1H2, NR1H3, CYP46A1 KMT2A 2373/4885MEN1 4346/4885LMNA 1326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.